OPINION: "NO MAGIC PRP"

Jane Y. Chin, Ph.D. et al (Unpublished, 2023)

Commercial PRP systems in the United States lack standard interpretation normalized to volume of donor blood drawn. Manufacturers’ PRP kit assay-data submitted to the FDA are not published for peer-review, leaving healthcare providers and researchers to rely on marketing claims or independent evaluations by academic researchers. None of the 7 current PRP classification approaches have been adopted in clinical practice, and standard dose-response studies for PRP orthobiologic applications are lacking. 

Regardless of data origin or centrifugation steps (number of "spins"), normalizing platelet yield by total blood volume required shows platelet numbers range from 73 to 180 (average 125.5 +/- 53.1) million per milliliter of drawn blood. Heterogeneity of platelet yield occurs in the same commercial systems conducted by the same laboratories, further negating the clinical relevance of commercial "X concentration" claims. Recent knee osteoarthritis data suggest PRP impaired responders showed higher absolute platelet counts compared to PRP responders, with twice the concentration of pro-angiogenic growth factors VEGF and EGF without significantly higher TGF-b1 in their PRP. 

Given that platelet concentrations of commercial PRP kits come from healthy donors and not patients, a critical aspect of future PRP data quality control should include analyses of normalized platelet counts in “clinical responders” versus “clinical sub-optimal-” or “clinical non-responders” when evaluating any commercial PRP devices.

Field Medical Affairs/Medical Science Liaison (MSL) Magazine/Journal Pubs

• Certification for the Medical Science Liaison: An Idea Whose Time Has Come — or Not. Drug Information Association Journal 2011. (with Jimmy Black and Ken Massey)

• Do the Right Thing: A Masterclass in Working with MSLs. Pharmaceutical Representative 2011.

• Medical science liaisons: A look to the future. Journal of Medical Marketing 2008 [06/2008; 8(3):193-197] (with Peter Dumovic)

• Ensuring MSLs Stick to the Science. Off-Label Communications: A Guide to Sales & Marketing Compliance 2008/2010 Editions. (with Bruce Armon / Book Chapter)

• Measuring performance of field-medical programmes: Medical science liaison metrics consensus. Journal of Commercial Biotechnology 2007 Jane Chin.

• PharmaVoice 100 Most Inspiring People of 2006: The Risk Takers / Dr. Jane Chin: What Glass Ceiling? (Archive)

• Chapter 9 The Role of Pharma’s Field Based Professionals in Patient Compliance. Patient Compliance: Sweetening the Pill 2006.

• Relationship, Risk, and Reinvention: Lessons from Field-based Medical Programmes. Journal of the British Association of Pharmaceutical Physicians 2006.

• Marketing to Professionals: MSLs: Off-Label Promotion. Pharmaceutical Executive 2005.

• Biotechnology’s Special Forces: Field-based medical science liaisons. Journal of Commercial Biotechnology 2004 [02/2004; 10:312-318]

• Canaries in the Coal Mine: MSLs in Competitive Intelligence. Pharmaceutical Executive 2004. (with Ben Gilad, Ph.D.)